newsfilter
← Latest News
Business Wire·

Sierra Oncology Reports 2021 Year End Results

– Planned Q2 2022 NDA submission following positive topline data from MOMENTUM clinical trial of momelotinib in symptomatic and anemic myelofibrosis patients – – Financial position significantly strengthened – Sierra Oncology, Inc. (NASDAQ